Research
Response to Standard PBC Treatment at 1 Year Linked to Lower Long-Term Risks
The Brief
- A biochemical response to ursodeoxycholic acid (UDCA) at 12 months was associated with lower 5-year risks of hepatic decompensation and mortality in patients with primary biliary cholangitis (PBC).
- The finding comes from a propensity-matched landmark analysis.
Why it matters
It suggests that response to standard UDCA therapy at one year may help clinicians identify PBC patients with better long-term outcomes.
Who’s affected
- clinicians treating primary biliary cholangitis
- patients with primary biliary cholangitis
- #primary biliary cholangitis
- #ursodeoxycholic acid
- #liver disease
- #hepatology
- #treatment response
(MedPage Today) -- A biochemical response to ursodeoxycholic acid (UDCA) at 12 months was associated with lower 5-year risks of hepatic decompensation and mortality in patients with primary biliary cholangitis (PBC), a propensity-matched landmark...